1 / 8

BDMC Report and Perspective

BDMC Report and Perspective. Constantine Gatsonis, PhD ACRIN Biostatistics and Data Management Center Brown University. BDMC 2009 -2010: Highlights. Developing and launching new studies: Cancer : 6681 , 6685, 6686, 6687, 6688, 6689, 6690, 6691, 6692, 6693, 6694, 6695, 4006

viveca
Download Presentation

BDMC Report and Perspective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BDMC Report and Perspective • Constantine Gatsonis, PhD • ACRIN Biostatistics and Data Management Center • Brown University

  2. BDMC 2009-2010: Highlights • Developing and launching new studies: • Cancer: 6681, 6685, 6686, 6687, 6688, 6689, 6690, 6691, 6692, 6693, 6694, 6695, 4006 • Cardiovascular: 4005, 4701 • Analyzing data for primary and secondary papers and abstracts: • 6652, 6654, 6657, 6660, 6661, 6664, 6665, 6666, 6667, 6668, 6673, 6677, 6683 • Pursuing new research and funding opportunities: AHRQ funding for RESCUE

  3. Themes of new studies • Deciphering the link of tests to outcomes • CT Angiography vs usual care ( 4005 and 4701- the RESCUE study) • Pre-op MRI for breast cancer (6694, with ACOSOG) • Accuracy in diagnosis and staging • DCE-CT vs DCE-MRI for HCC (6690) • PET/CT for H&N cancer (6685) • Imaging-based biomarkers for predicting response and long term outcomes.

  4. Building the outcomes enterprise: ACRIN in the CER era • Methodologic challenges CER calls for illuminating the complex path: Dx information Outcomes The main pathway goes through therapy

  5. Building the outcomes enterprise: ACRIN in the CER era • Randomized studies • address many of the methodologic difficulties • but can be large, lengthy, and costly. • ACRIN has unique scientific expertise, practical experience and infrastructure to pursue them Dx information Outcomes

  6. Building the outcomes enterprise: ACRIN in the CER era • Observational studies • Registries (e.g. NOPR) • Linkage of clinical trial data and secondary databases (CMS, EMR) • Important opportunities for ACRIN • Area for current GO grant (Dartmouth, Brown, NOPR, Tufts EPC), built around ACRIN’s Outcomes Committee and NOPR Dx information Outcomes

  7. Building the outcomes enterprise: ACRIN in the CER era • Modeling studies • To assess the impact on outcomes using the findings from ACRIN trials ( DMIST, NLST, NCTCC, 6666) • To combine information from ACRIN trials with others from the literature (CISNET ) • Area for to develop, with leadership from ACRIN’s Outcomes Committee Dx information Outcomes

  8. The scope of ACRIN research (if we can ensure appropriate funding !) CER era Dx information Outcomes

More Related